4DMedical (ASX:4DX) announced a landmark distribution agreement with Philips, marking a significant commercialisation pathway in the US market.
The five-year agreement grants Philips exclusive distribution rights to 4DMedical’s suite of products with US government customers and non-exclusive rights to all other US commercial customers.
Under the terms of the agreement, Philips will leverage its extensive US commercial partnerships, including those with the Department of Veterans Affairs and the Department of Defense.
The collaboration aims to address respiratory conditions triggered by deployment-related toxic exposure, with 4DMedical's cutting-edge software solutions integrated into Philips’ product offerings.
Andreas Fouras, MD/CEO and Founder of 4DMedical, stated, "The agreement with Philips sets a new benchmark in lung health and transforms our ability to deliver our technology to patients and their doctors. Together, Philips and 4DMedical will deliver lung function analyses for all lung disorders, including unexplained dyspnoea, asthma, COPD, and interstitial lung disease."
This agreement capitalises on Philips’ strong presence and longstanding relationships within the VA and DoD sectors, where Philips has been providing innovative solutions for over 45 years.
The collaboration is expected to significantly support the PACT Act, benefiting 6 million Veterans exposed to airborne hazards during deployment.
The collaboration is set to reshape the landscape of respiratory health solutions in the US, ensuring advanced care for millions of Veterans and patients.
4DMedical is an ASX-listed medical technology company. Through its flagship patented XV Technology, the company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe.